Valley fever, a fungal infection caused by Coccidioides fungi found in dry soil across the western United States, continues to pose a growing public health challenge, particularly in California where cases have climbed to historic levels. This year, the state has reported more than 12,700 cases, up from just over 1,400 two decades ago, reflecting a long-term upward trend. The disease typically enters the body through inhalation of airborne fungal spores, with about 40% of exposed individuals developing symptoms ranging from mild respiratory illness to severe disseminated disease affecting the brain and spinal cord.

Treatment for advanced valley fever, especially when the infection spreads beyond the lungs, is difficult and prolonged. Currently used antifungal medications such as fluconazole and itraconazole suppress fungal growth but can cause significant side effects, including hair loss and skin problems. Additionally, the disease is often misdiagnosed in its early stages due to symptom overlap with influenza, COVID-19, and other respiratory illnesses, which can delay critical treatment.

Researchers are now exploring olorofim, a novel antifungal drug that directly kills the fungus rather than merely containing its growth. In a recent multistate study published in the Annals of Internal Medicine, 41 patients with severe valley fever were treated with olorofim between May 2019 and August 2022. Most patients were previously healthy before infection, underscoring the disease’s capability to cause serious illness even in those without weakened immune systems. The majority—30 of the participants—had infections that had spread to the central nervous system, with some requiring surgically implanted devices to manage pressure caused by the infection.

Results from the trial showed promising outcomes: by day 42 of treatment, over 75% of patients had improved or their condition had stabilized, and by day 84, about 73% maintained these positive results. Experts involved in the study described the treatment as a “salvage” option for cases where standard drugs failed, offering hope for more effective management of severe disease. Although the drug is not yet approved by the U.S. Food and Drug Administration (FDA) for valley fever treatment, compassionate use requests are available for patients in dire need.

Medical professionals note that while ongoing research is needed to determine the long-term use and potential as a first-line treatment, olorofim represents an important advance for those with complicated valley fever infections. The increasing number of cases and rising severe illness incidence—partly attributed to a growing immunocompromised population—fuel optimism that new antifungal therapies like olorofim will expand treatment options in the future.

In the meantime, experts urge heightened awareness among healthcare providers and patients, especially those living in or visiting endemic regions such as California’s San Joaquin Valley and parts of Arizona, to consider valley fever in cases of persistent respiratory symptoms or unexplained neurological issues. Early detection remains crucial for improving outcomes in this often underestimated but potentially deadly disease.